Frank-Ito Dennis Onyeka, Cohen Seth Morris
Department of Head and Neck Surgery & Communication Sciences, Duke University Medical Center, Durham, North Carolina, USA.
Computational Biology & Bioinformatics PhD Program, Duke University, Durham, North Carolina, USA.
Otolaryngol Head Neck Surg. 2021 Apr;164(4):829-840. doi: 10.1177/0194599820959674. Epub 2020 Oct 13.
Adjuvant management for laryngotracheal stenosis (LTS) may involve inhaled corticosteroids, but metered dose inhalers are designed for pulmonary drug delivery. Comprehensive analyses of drug particle deposition efficiency for orally inhaled corticosteroids in the stenosis of LTS subjects are lacking.
Descriptive research.
Academic medical center.
Anatomically realistic 3-dimensional reconstructions of the upper airway were created from computed tomography images of 4 LTS subjects-2 subglottic stenosis and 2 tracheal stenosis subjects. Computational fluid dynamics modeling was used to simulate airflow and drug particle transport in each airway. Three inhalation pressures were simulated, 10 Pa, 25 Pa, and 40 Pa. Drug particle transport was simulated for 100 to 950 nanoparticles and 1 to 50 micron-particles. Particles were released into the airway to mimic varying inhaler conditions with and without a spacer chamber.
Based on smallest to largest cross-sectional area ratio, the laryngotracheal stenotic segment shrunk by 57% and 47%, respectively, for subglottic stenosis models and by 53% for both tracheal stenosis models. Airflow resistance at the stenotic segment was lower in subglottic stenosis models than in tracheal stenosis models: 0.001 to 0.011 Pa.s/mL vs 0.024 to 0.082 Pa.s/mL. Drug depositions for micron-particles and nanoparticles at stenosis were 0.06% to 2.48% and 0.10% to 2.60% for subglottic stenosis and tracheal stenosis models, respectively. Particle sizes with highest stenotic deposition were 6 to 20 µm for subglottic stenosis models and 1 to 10 µm for tracheal stenosis models.
This study suggests that at most, 2.60% of inhaled drug particles deposit at the stenosis. Particle size ranges with highest stenotic deposition may not represent typical sizes emitted by inhalers.
喉气管狭窄(LTS)的辅助治疗可能会用到吸入性糖皮质激素,但定量吸入器是为肺部给药设计的。目前缺乏对LTS患者狭窄部位口服吸入糖皮质激素药物颗粒沉积效率的综合分析。
描述性研究。
学术医疗中心。
根据4例LTS患者(2例声门下狭窄和2例气管狭窄患者)的计算机断层扫描图像创建上呼吸道的逼真三维重建模型。采用计算流体动力学建模来模拟每个气道中的气流和药物颗粒传输。模拟了三种吸入压力,分别为10 Pa、25 Pa和40 Pa。对100至950纳米颗粒和1至50微米颗粒的药物颗粒传输进行了模拟。在有和没有储雾罐的情况下,将颗粒释放到气道中以模拟不同的吸入器条件。
基于最小到最大横截面积比,声门下狭窄模型的喉气管狭窄段分别缩小了57%和47%,气管狭窄模型的狭窄段缩小了53%。声门下狭窄模型狭窄段的气流阻力低于气管狭窄模型:0.001至0.011 Pa·s/mL 对比 0.024至0.082 Pa·s/mL。声门下狭窄和气管狭窄模型中,狭窄部位微米颗粒和纳米颗粒的药物沉积分别为0.06%至2.48%和0.10%至2.60%。声门下狭窄模型中狭窄部位沉积最高的颗粒大小为6至20 µm,气管狭窄模型为1至10 µm。
本研究表明,最多2.60%的吸入药物颗粒沉积在狭窄部位。狭窄部位沉积最高的颗粒大小范围可能并不代表吸入器喷出的典型颗粒大小。